212 related articles for article (PubMed ID: 16107991)
1. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence.
Sullivan LE; Fiellin DA
Clin Infect Dis; 2005 Sep; 41(6):891-6. PubMed ID: 16107991
[TBL] [Abstract][Full Text] [Related]
2. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.
Sullivan LE; Metzger DS; Fudala PJ; Fiellin DA
Addiction; 2005 Feb; 100(2):150-8. PubMed ID: 15679744
[TBL] [Abstract][Full Text] [Related]
3. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ; Laine C; Lin YT; Lynch K
Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
[TBL] [Abstract][Full Text] [Related]
4. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
[TBL] [Abstract][Full Text] [Related]
5. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
[TBL] [Abstract][Full Text] [Related]
6. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
[TBL] [Abstract][Full Text] [Related]
7. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
8. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine use: the international experience.
Carrieri MP; Amass L; Lucas GM; Vlahov D; Wodak A; Woody GE
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S197-215. PubMed ID: 17109307
[TBL] [Abstract][Full Text] [Related]
10. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents.
McCance-Katz EF
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S89-95. PubMed ID: 16265622
[TBL] [Abstract][Full Text] [Related]
11. HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.
Lott DC; Strain EC; Brooner RK; Bigelow GE; Johnson RE
J Subst Abuse Treat; 2006 Sep; 31(2):187-94. PubMed ID: 16919747
[TBL] [Abstract][Full Text] [Related]
12. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between buprenorphine and antiretroviral medications.
Bruce RD; McCance-Katz E; Kharasch ED; Moody DE; Morse GD
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S216-23. PubMed ID: 17109308
[TBL] [Abstract][Full Text] [Related]
14. Substance use of disorders in HIV-infected patients: impact and new treatment strategies.
Fiellin DA
Top HIV Med; 2004; 12(3):77-82. PubMed ID: 15310938
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
16. Comparison of costs and utilization among buprenorphine and methadone patients.
Barnett PG
Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
[TBL] [Abstract][Full Text] [Related]
17. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
[TBL] [Abstract][Full Text] [Related]
18. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B; Lucas GM; Carrieri MP
Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
[TBL] [Abstract][Full Text] [Related]
19. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.
Altice FL; Sullivan LE; Smith-Rohrberg D; Basu S; Stancliff S; Eldred L
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S178-83. PubMed ID: 17109304
[TBL] [Abstract][Full Text] [Related]
20. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.
Cunningham CO; Sohler NL; McCoy K; Kunins HV
Fam Med; 2006 May; 38(5):336-40. PubMed ID: 16673195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
